Reece Caldwell

Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance

Christina Guo, Adam Sharp, Bora Gürel et al. · Nature · 2023 · 103 citations · Full text

First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors.

Johann S. de Bono, David S.P. Tan, Reece Caldwell et al. · Journal of Clinical Oncology · 2019 · 30 citations

Pathology, Advanced Solid Tumors, Tumor Biology +19

Abstract CT143: Phase I study of the combination of a RAF-MEK inhibitor CH5126766 and FAK inhibitor defactinib in an intermittent dosing schedule with expansions in <i>KRAS</i> mutant cancers

Rajiv Shinde, Angelika Terbuch, Martin Little et al. · Cancer Research · 2020 · 21 citations

Pharmacotherapy, Tumor Biology, Molecular Pharmacology +20

Targeting homologous recombination deficiency in uterine leiomyosarcoma

Genevieve Dall, Cassandra J. Vandenberg, Ksenija Nesic et al. · Journal of Experimental & Clinical Cancer Research · 2023 · 21 citations · Full text

Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial

Susana Banerjee, Matthew Krebs, Alastair Greystoke et al. · Nature Medicine · 2025 · 13 citations · Full text